Eupatilin exerts neuroprotective effects in mice with transient focal cerebral ischemia by reducing microglial activation (original) (raw)
Fig 2
Eupatilin reduces brain damage in tMCAO-challenged mice.
Mice were challenged with tMCAO and eupatilin (Eup: 1, 3, and 10 mg/kg, p.o.) was given to mice immediately after tMCAO. Alternatively, 10 mg/kg eupatilin was given to mice 5 hours after MCAO induction. Effects of eupatilin on brain infarct volume (A and B), neurological function (C), and neural cell death (D) were assessed 22 h after reperfusion. Edaravone (Eda, 3 mg/kg, p.o.) was used as a positive control. (A) Representative images of TTC-stained brain slices indicating brain infarction. (B) Quantification of infarct volume. (C) Neurological score reflecting neurological functions. n = 10~15 per group. **P<0.01 and ***P<0.001 versus the vehicle-treated tMCAO group (tMCAO+veh). (D) Effects of eupatilin (Eup, 10 mg/kg, p.o.) administration immediately after tMCAO on neural cell death. Representative images of FJB-stained sections. Diagram boxes display the cerebral area where the images in middle and bottom panels were acquired. Dashed lines indicate the lesion site. Scale bars, 200 μm (top panels) and 50 μm (middle and bottom panels).